Prediction of risk for Type 2 Diabetes development.
BelDIA PRE® is an easy to use screening test device for patients, clinics and physians. By determination of fasting plasma concentration of intact proinsulin, the test describes development of type 2 diabetes mellitus even up to one years prior to glucose elevation. It is designed as a point-of-care device to provide immediate results.
The early test is working with a lateral-flow based technology similar to a pregnancy test. The result is provided in a qualitative way and is either “positive” or “negative”. One drop of blood capillary blood (40 µl) is needed, e.g. obtained by pricking the fingertip.